Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1998 1
2003 1
2004 1
2005 1
2007 2
2008 1
2011 6
2012 3
2013 3
2014 4
2015 4
2016 6
2017 6
2018 6
2019 5
2020 8
2021 7
2022 7
2023 9
2024 9
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ. de Wild SR, et al. Among authors: de munck l. Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952707
De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
de Wild SR, van Roozendaal LM, de Wilt JHW, van Dalen T, van der Hage JA, van Duijnhoven FH, Simons JM, Schipper RJ, de Munck L, van Kuijk SMJ, Boersma LJ, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, van de Vijver KKBT, de Vries J, Westenberg AH, Strobbe LJA, Smidt ML. de Wild SR, et al. Among authors: de munck l. Br J Surg. 2024 Apr 3;111(4):znae077. doi: 10.1093/bjs/znae077. Br J Surg. 2024. PMID: 38597154 Free PMC article.
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC, van der Voort A, van Ramshorst MS, Sanders J, Vonk S, Horlings HM, Siesling S, de Munck L, van Leeuwen AE, Kleijn M, Mittempergher L, Kuilman MM, Glas AM, Wesseling J, Lips EH, Sonke GS. Liefaard MC, et al. Among authors: de munck l. Breast Cancer Res. 2023 Jun 19;25(1):71. doi: 10.1186/s13058-023-01664-x. Breast Cancer Res. 2023. PMID: 37337299 Free PMC article.
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
Liefaard MC, van der Voort A, van Seijen M, Thijssen B, Sanders J, Vonk S, Mittempergher L, Bhaskaran R, de Munck L, van Leeuwen-Stok AE, Salgado R, Horlings HM, Lips EH, Sonke GS. Liefaard MC, et al. Among authors: de munck l. NPJ Breast Cancer. 2024 Apr 18;10(1):29. doi: 10.1038/s41523-024-00636-4. NPJ Breast Cancer. 2024. PMID: 38637568 Free PMC article.
Diagnostics in Patients Suspect for Breast Cancer in The Netherlands.
Voets MM, Groothuis-Oudshoorn CGM, Veneklaas LHJ, Manohar S, Brinkhuis M, Veltman J, de Munck L, de Geus-Oei LF, Broeders MJM, Siesling S. Voets MM, et al. Among authors: de munck l. Curr Oncol. 2021 Nov 29;28(6):4998-5008. doi: 10.3390/curroncol28060419. Curr Oncol. 2021. PMID: 34940058 Free PMC article.
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.
Eijkelboom AH, de Munck L, Menke-van der Houven van Oordt CW, Broeders MJM, van den Bongard DHJG, Strobbe LJA, Mureau MAM, Lobbes MBI, Westenend PJ, Koppert LB, Jager A, Siemerink EJM, Wesseling J, Verkooijen HM, Vrancken Peeters MTFD, Smidt ML, Tjan-Heijnen VCG, Siesling S; NABON-COVID-19 Consortium; COVID and Cancer Care-NL Consortium. Eijkelboom AH, et al. Among authors: de munck l. Breast Cancer Res Treat. 2023 Jan;197(1):161-175. doi: 10.1007/s10549-022-06732-y. Epub 2022 Nov 5. Breast Cancer Res Treat. 2023. PMID: 36334188 Free PMC article.
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Robinson JG, et al. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030. JAMA. 2014. PMID: 24825642 Clinical Trial.
81 results